Evolution and development of drug review expert advisory systems in ChinaLI Feng, WU Xiao-ming2081-2087
Introduction to the new technical requirements and challenges of the draft ICH S5(R3) guideline on reproductive toxicity for human pharmaceuticalsZHANG Li-jiang, HUANG Fang-hua2088-2097
Analysis of control limit of DNA reactive/mutagenic impurities under ICH M7GAO Guang-hua, YU Chun-rong, LI Hong-xia, WANG Qing-li, DA Hong-yuan, MA Lei2098-2106
Considerations on post marketing real world data collection for pediatric drugs in ChinaGENG Ying, ZHAO De-heng, YANG Zhi-min2107-2110
Introduction to EMA non-clinical evaluation of radiopharmaceuticals for medical diagnosisGUANG Hong-mei, WANG Qing-li2111-2115
Considerations on quality equivalence evaluation of generic topical dermatologic drugsGUO Di-liang, XU Ping-wei, WANG Ya-min2116-2120
Related issues and consideration on China's import of plant medicine registrationAN Na, ZHOU Bei, TANG Jian-yuan2121-2123
A review of formulations and devices of nebulizer drug productsGAO Lei, WANG Ya-min, MA Yu-nan, NING Li-li, YAO Fang-yao2124-2126
Safety concerns of drug-induced phospholipidosis and strategy for risk managementYU Shan-shan, YIN Hua-jing, WANG Yin, WU Shuang, LI Zheng, YIN Mao-shan, HU Xiao-min2131-2136